Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades

Influenza and other Respiratory Viruses

Volumn 5, Issue 1, 2011, Pages 13-23

  Bragstad, Karoline ^a   Martel, Cyril J ^b   Thomsen, Joakim S ^a   Jensen, Kim L ^b   Nielsen, Lars P ^a   Aasted, Bent ^b   Fomsgaard, Anders ^a  

^a Statens Serum Institut   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cross reactive immunity; DNA vaccine; Influenza; Pandemic influenza

Indexed keywords

DNA VACCINE; HEMAGGLUTININ; MATRIX PROTEIN; NUCLEOPROTEIN; SIALIDASE;

ARTICLE; CONTROLLED STUDY; FERRET; GENE GUN; HONG KONG INFLUENZA; HUMAN; INFLUENZA VACCINATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPANISH INFLUENZA; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; DISEASE MODELS, ANIMAL; FERRETS; HONG KONG; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; SPAIN; VACCINATION; VACCINES, DNA; VIRAL PROTEINS;

EID: 78650097650     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2010.00177.x     Document Type: Article

References (49)

1. Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 2000; 18(11-12):957-1030.
2. Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007 Apr 18; (2):CD001269.
3. Ulmer JB, Wahren B, Liu MA. Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 2006; 12(5):216-222.
4. Liu MA, Wahren B, Karlsson Hedestam GB. DNA vaccines: recent developments and future possibilities. Hum Gene Ther 2006; 17(11):1051-1061.
5. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008; 9(10):776-788.
6. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006; 24(21):4475-4481.
7. Jones S, Evans K, McElwaine-Johnn H et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009; 27(18):2506-2512.
8. Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008; 7(2):175-191.
9. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 2002; 76(1):105-115.
10. Tumpey TM, Basler CF, Aguilar PV et al. Characterization of the reconstructed 1918 spanish influenza pandemic virus. Science 2005; 310(5745):77-80.
11. Yu X, Tsibane T, McGraw PA et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008; 455(7212):532-536.
12. Vinner L, Therrien D, Wee E et al. Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1. APMIS 2006; 114(10):690-699.
13. Ljungberg K, Rollman E, Eriksson L, Hinkula J, Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 2002; 302(1):44-57.
14. Bragstad K, Jorgensen PH, Handberg KJ, Mellergaard S, Corbet S, Fomsgaard A. New avian influenza A virus subtype combination H5N7 identified in Danish mallard ducks. Virus Res 2005; 109(2):181-190.
15. Corbet S, Vinner L, Hougaard DM et al. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons. AIDS Res Hum Retroviruses 2000; 16(18):1997-2008.
16. Finter NB. Quantitative haemadsorption, a new assay technique. I. Assay and interferon. Virology 1964; 24:589-597.
17. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. J Exp Med 1938; 27:493-497.
18. Spackman E, Senne DA, Myers TJ et al. Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes. J Clin Microbiol 2002; 40(9):3256-3260.
19. Martel CJ, Aasted B. Characterization of antibodies against ferret immunoglobulins, cytokines and CD markers. Vet Immunol Immunopathol 2009; 132(2-4):109-115.
20. WHO. WHO manual on animal influenza diagnosis and surveillance. [WHO/CDC/NCS/2002.5]. 2009.
21. Gupta R, Jung E, Brunak S. Prediction of N-glycosylation sites in human proteins. 2004. (In Preparation).
22. Bragstad K, Nielsen LP, Fomsgaard A. The evolution of human influenza A viruses from 1999 to 2006: a complete genome study. Virol J 2008; 5:40.
23. Reichert T, Chowell G, Nishiura H, Christensen RA, McCullers JA. Does Glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza? BMC Infect Dis 2010; 10:5.
24. Vigerust DJ, Ulett KB, Boyd KL, Madsen J, Hawgood S, McCullers JA. N-linked glycosylation attenuates H3N2 influenza viruses. J Virol 2007; 81(16):8593-8600.
25. Wang B, Boyer J, Srikantan V et al. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. DNA Cell Biol 1993; 12(9):799-805.
26. Laddy DJ, Yan J, Khan AS et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009; 83(9):4624-4630.
27. Wolf YI, Viboud C, Holmes EC, Koonin EV, Lipman DJ. Long intervals of stasis punctuated by bursts of positive selection in the seasonal evolution of influenza A virus. Biol Direct 2006; 1:34.
28. Tumpey TM, Garcia-Sastre A, Taubenberger JK, Palese P, Swayne DE, Basler CF. Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci USA 2004; 101(9):3166-3171.
29. Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 2000; 68(6):793-806.
30. Yewdell JW, Bennink JR, Smith GL, Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1985; 82(6):1785-1789.
31. Epstein SL, Kong WP, Misplon JA et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005; 23(46-47):5404-5410.
32. Bizebard T, Gigant B, Rigolet P et al. Structure of influenza virus haemagglutinin complexed with a neutralizing antibody. Nature 1995; 376(6535):92-94.
33. Johansson BE, Bucher DJ, Kilbourne ED. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 1989; 63(3):1239-1246.
34. Colman PM, Ward CW. Structure and diversity of influenza virus neuraminidase. Curr Top Microbiol Immunol 1985; 114:177-255.
35. Kilbourne ED, Johansson BE, Grajower B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc Natl Acad Sci USA 1990; 87(2):786-790.
36. Chen Z, Kadowaki S, Hagiwara Y et al. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 2000; 18(28):3214-3222.
37. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4(2):e59.
38. Glezen WP, Couch RB, Six HR. The influenza herald wave. Am J Epidemiol 1982; 116(4):589-598.
39. Tumpey TM, Garcia-Sastre A, Taubenberger JK et al. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol 2005; 79(23):14933-14944.
40. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982; 31(2 Pt 1):417-427.
41. Kodihalli S, Haynes JR, Robinson HL, Webster RG. Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin. J Virol 1997; 71(5):3391-3396.
42. Kodihalli S, Goto H, Kobasa DL, Krauss S, Kawaoka Y, Webster RG. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol 1999; 73(3):2094-2098.
43. Kodihalli S, Kobasa DL, Webster RG. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 2000; 18(23):2592-2599.
44. Klenk HD, Wagner R, Heuer D, Wolff T. Importance of hemagglutinin glycosylation for the biological functions of influenza virus. Virus Res 2002; 82(1-2):73-75.
45. Reid AH, Fanning TG, Hultin JV, Taubenberger JK. Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. Proc Natl Acad Sci USA 1999; 96(4):1651-1656.
46. Sui J, Hwang WC, Perez S et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16(3):265-273.
47. Stropkovska A, Mucha V, Fislova T, Gocnik M, Kostolansky F, Vareckova E. Broadly cross-reactive monoclonal antibodies against HA2 glycopeptide of Influenza A virus hemagglutinin of H3 subtype reduce replication of influenza A viruses of human and avian origin. Acta Virol 2009; 53(1):15-20.
48. Yoshida R, Igarashi M, Ozaki H et al. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog 2009; 5(3):e1000350.
49. Ulmer JB. Influenza DNA vaccines. Vaccine 2002; 20(Suppl 2):S74-S76.